CVS Health Corp vs Lufax Holding Ltd — how do they compare? CVS Health Corp trades at $86.43 (market cap $112.49B), while Lufax Holding Ltd trades at $0.96 (market cap $1.01B). The key difference: CVS Health Corp is far larger — about 111.4× Lufax Holding Ltd's market cap, and CVS Health Corp pays a 3.02% dividend while Lufax Holding Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold CVS Health Corp for 83 Days and Lufax Holding Ltd for 13 Days on average.
| CVS | LU | |
|---|---|---|
Market Cap | $112.49B | $1.01B |
Volume | 8,467,392 | 4,754,976 |
Sector | Health | Financials |
52-Week High | $110.60 | $3.93 |
52-Week Low | $70.08 | $0.95 |
Typical Hold Time | 83 Days | 13 Days |
Enterprise Value | $174.83B | $59.02B |
Dividend Yield | 3.02% | — |
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $87.80, up 1.59% today, with strong analyst support (85% buy ratings) and a $111.20 consensus price target suggesting 27% upside. Recent quarterly earnings have consistently beaten expectations, with Q2 2026 EPS of $2.58 surpassing the $1.87 estimate. Revenue growth remains solid, reaching $402.07B in 2025, though net margins compressed to 1.18%. The technical picture shows bullish momentum with current price near key support at $87.
CVS presents a compelling value opportunity with attractive valuation multiples (P/E 23.21, P/S 0.27) and dividend stability, but faces margin pressure from healthcare cost trends. The stock's upside depends on maintaining earnings momentum amid reimbursement challenges and regulatory scrutiny highlighted in recent legal investigations.
LU trades at $0.98, down 2.83% today, with a bearish technical signal despite oscillators showing some bullish momentum. The company reported a net loss of $2.10 billion on $23.11 billion revenue in 2025, with negative profit margins and declining revenue trends. Recent corporate actions include a 10:1 reverse stock split effective October 2026. Analyst consensus remains predominantly bullish with 69% buy ratings, citing deep value potential despite ongoing operational challenges.
LU presents a high-risk, event-driven opportunity with significant valuation discounts (P/S 0.26, P/B 0.07) but faces substantial execution risks amid regulatory pressures and persistent losses. The stock's outlook hinges on successful restructuring and potential Hong Kong listing catalysts, though near-term headwinds from China's consumer lending sector remain challenging for profitability recovery.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →Lufax Holding Ltd is a leading financial technology (fintech) platform in China. The company operates a technology-driven personal financial services platform that offers a wide range of loans and wealth management products to its users. Lufax primarily serves the rapidly growing wealth and consumption needs of China’s mass affluent and affluent populations through a combination of its digital platform and an extensive offline network.
Read more on LU →